Table 3.
Outcomes of treating COVID-19 with IVM-based protocols.
|
| |||||
|---|---|---|---|---|---|
| REPORT TYPE | SOURCE OF EVIDENCE | TOTAL | POSITIVE | NEGATIVE | INCONCLUSIVE |
|
| |||||
| Structured analyses | Clinical practice guidelines | 5 | 0 | 4 | 1 |
|
| |||||
| Meta-analyses, Systematic reviews | 31 | 1 | 3 | 27 | |
|
| |||||
| Clinical studies | Randomized control trials (RCTs) | 27 | 6 | 17 | 4 |
|
| |||||
| Cohort studies, Case control studies | 22 | 6 | 9 | 7 | |
|
| |||||
| Case reports, Case series |
8 | 1 | 0 | 7 | |
|
| |||||
| Population studies | 4 | 2 | 0 | 2 | |
|
| |||||
| Non-systematic Reviews | Narratives | 106 | 6 | 2 | 98 |
|
| |||||
| Expert opinions | 1 | 0 | 0 | 1 | |
|
| |||||
| Editorials | 0 | 0 | 0 | 0 | |
|
| |||||
| Mechanisms of action | In-silico studies | 28 | 14 | 3 | 11 |
|
| |||||
| In-vitro studies | 19 | 9 | 4 | 6 | |
|
| |||||
| In-vivo studies | 14 | 8 | 3 | 3 | |
|
| |||||
| Total | 265 | 53 | 45 | 167 | |
|
| |||||